The Library
c-Myc and downstream targets in the pathogenesis and treatment of cancer
Tools
Tools
Tools
Robson, Samuel Charles, Pelengaris, Stella and Khan, Michael (2006) c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Patents on Anti-Cancer Drug Discovery, Vol.1 (No.3). pp. 305-326. doi:10.2174/157489206778776934
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://www.benthamscience.com/contents-JCode-PRA-V...
Abstract
The c-Myc oncoprotein is a master regulator of genes involved in diverse cellular processes. Situated upstream of signalling pathways regulating cellular replication/growth as well as apoptosis/growth arrest, c-Myc may help integrate processes determining cell numbers and tissue size in physiology and disease. In cancer, this 'dual potential' allows cMyc to act as its own tumour suppressor. Evidently, given that deregulated expression of c-Myc is present in most, if not all, human cancers (Table 1) and is associated with a poor prognosis, by implication these in-built 'failsafe' mechanisms have been overcome.
To explore the complex activity of c-Myc and its potential as a therapeutic target 'post-genome era' technologies for determining global gene expression alongside advanced new models for the study of tumourigenesis in vivo have proved invaluable. Thus, many recent studies have provided encouragement for the therapeutic targeting of c-Myc in cancer and have revealed new protein targets for manipulating aspects of c-Myc activity. The remarkable regression of even advanced and genetically unstable tumours, seen following deactivation of c-Myc in various models is particularly exciting.
This review will discuss what is known about the role of c-Myc in growth deregulation and cancer and will conclude with a discussion of the most promising recent developments in Myc-targeted therapeutics.
| Item Type: | Journal Item | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RS Pharmacy and materia medica |
||||
| Divisions: | Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) | ||||
| Journal or Publication Title: | Recent Patents on Anti-Cancer Drug Discovery | ||||
| Publisher: | Bentham Science Publishers Ltd. | ||||
| ISSN: | 1574-8928 | ||||
| Official Date: | November 2006 | ||||
| Dates: |
|
||||
| Volume: | Vol.1 | ||||
| Number: | No.3 | ||||
| Number of Pages: | 22 | ||||
| Page Range: | pp. 305-326 | ||||
| DOI: | 10.2174/157489206778776934 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Related URLs: |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
